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ABSTRACT 
 
This study describes a simple high performance liquid chromatographic (HPLC) method for the determination of 
clindamycin in plasma. Analysis was carried out using a Varian® Pro Star HPLC unit equipped with an online 
degasser. A reversed-phase ACE® C18 column of dimensions 250x4.6mm, particle size 5µm was used. The mobile 
phase was made up of 0.02M disodiumhydrogen phosphate buffer (pH of 2.9) and acetonitrile at a ratio of 71:29 
v/v, running through the column at a flow rate of 1.5ml/min and with ultraviolet (UV) detection set at a wavelength 
of 195nm. Clindamycin was separated from plasma proteins by protein precipitation with ice cold acetonitrile. 
Clindamycin and the internal standard phenobarbitone eluted after 3.96 and 7 minutes respectively. The method 
was validated for linearity in the working concentration range of 0.5-20µg/ml. Linearity was observed with a 
coefficient of determination (r2) of 0.990. The recoveries obtained were all above 82% and the limit of quantification 
and limit of detection were 0.2µg/ml and 0.1µg/ml respectively.  
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INTRODUCTION 
 
In spite of over 50 years of widespread clinical use since its introduction in the late 60’s, Clindamycin, described 
chemically as (2S,4R)-N-{2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl}-1-
methyl-4-propylpyrrolidine-2-carboxamide is a semi-synthetic derivative of Lincomycin and retains potent activity 
against many aerobic and anaerobic gram positive and gram negative pathogens which contribute to the 
development of skin and subcutaneous tissue infections, respiratory tract infections, septicaemia, abdominal 
infections and gynaecological infections [1].  
 
Clindamycin is a commonly prescribed antibiotic for the treatment of foot infections which develop as a result of 
peripheral arterial disease (PAD), which is a chronic and progressive disease of the peripheries. If not treated 
appropriately these infections may lead to gangrene of the extremities [2]. There are a number of  published studies 
which describe analytical methods for quantifying clindamycin using different techniques such as gas- liquid 
chromatography [3], chemiluminescence [4,5], adsorption stripping voltammetry [6] and ultra- performance liquid 
chromatography [7]. There are also a number of published High Performance Liquid Chromatography (HPLC) 
methods for the determination of clindamycin in plasma [3,8-10, 12-18]. HPLC is a popular method used for the 
analysis of drugs as it is sensitive, precise and relatively simple to use [19, 20]. There are HPLC methods for the 
determination of clindamycin which incorporate the use of chemical ionization-mass spectrometry [12,17] which is 
a useful detection technique for volatile substances [21] or coupled columns [22] which although increase resolution 
may not be readily available in many laboratories and may complicate analysis. Na Bangchang et al proposed a 
HPLC/UV method for the analysis of Clindamycin in plasma using liquid-liquid extraction with ethyl-acetate as the 
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sample preparation method. Final results presented
alternative method presents a shorter total run time. This method has a run time of less than 10 minutes which makes 
it more applicable for analysis of a larger number of samples. Such a method is to be later used for pharmacokinetic 
studies in patients suffering from Periphe
reproduced eliminating the use of liquid
reagent and time consuming. Liquid
of large quantities of organic solvents and poorer recoveries when compared to protein precipitation [2
proposed method by Liu et al published in 1997 describes a sample preparation method using solid 
(SPE) [10]. The sample was loaded onto a silica column, washed with deionized water and eluted with methanol 
several times. Silica columns used in solid phase extraction increase the costs of a study as they need to be replaced 
after every loading and elution and normally entail multiple preparation steps before the sample is eluted therefore 
lengthening the procedure.  
 
The proposed method makes use of a UV
partition chromatography [24]. This type of detector is 
other detectors such as mass spectrometer detectors.
 
Commonly used organic solvents in mobile p
more expensive than methanol and is said to be slightly more toxic [2
absorbance when compared to most other organic solvents. This produces lower noise levels by the UV detector. It 
also produces lower column pressure when mixed with aqueous solutions. For this reason it was decided to use 
acetonitrile as the organic component in the mobile phase. 
 
Clindamycin phosphate, known chemically as 
phosphono-1-thiopentopyranoside, is the pro drug of clindamycin used in parenteral formulations. It is more 
hydrophilic than clindamycin. When administered intravenously it is rapidly hydrolyzed to the biologically active 
clindamycin free base by the phosphatase enzyme [10].
Figure 1: 
 
Chemicals and Reagents  
Acetonitrile and Orthophosphoric acid were obtained from Fisher Scientific (Leicestershire, UK). Ultrapure 
analytical grade type 1 water (r > 18M
UK). Disodium hydrogen phosphate from Scharlau (Sentmen
Clindamycin hydrochloride powder
Germany) and standard Lincomycin powder from Sigma Aldrich (Steinheim, Germany) and 1
from Acros Organics (Belgium). All solvents were of HPLC grade standard.  
 
HPLC Instrumentation 
The study was carried out on a Varian ® Pro Star HPLC unit consisiting of an online degasser 
01488), column oven (model no. 1510) 
separated on a reversed-phase ACE® 5 C
size). An Agilent Pursuit 5 C18 Meta Guard® guard column (10 x 4.6mm) was also 
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 a total run time of 18 minutes [15]. The 
ral Arterial Disease. The proposed method is simple and can be readily 
-liquid extraction as a method of sample preparation which is known to be 
-liquid extraction is associated with incomplete phase separations, the disposal 
- visible detector - which is the most commonly used type of detector in 
more easily found in most laboratories having an HPLC than 
 
hases for HPLC are acetonitrile and methanol
6]. It however presents with a lower LC grade 
 
methyl 5-{2-chloro-1-[(1-methyl-4-propylprolyl)amino]pr
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Chromatographic Conditions and Mobile Phase Preparation 
The system was operated isocratically using a mobile phase consisting of a mixture of 0.02M disodium 
hydrogenphosphate buffer prepared at a pH of 2.9 (by the dropwise addition of orthophosphoric acid) and 
acetonitrile at a ratio of 71:29 v/v pumped at a flow rate of 1.5ml/min at 25°C. The sample was injected through a 
fixed sample loop having a volume of 50µl. The UV detector was set at 195nm.  
 
Procedures 
Clindamycin Hydrochloride vs Clindamycin Phosphate.  
During method development of this analytical procedure which will be later used to quantify the amount of 
clindamycin in plasma of patients receiving intravenous clindamycin phosphate, it would be better to observe the 
chromatographic behaviour of the hydrochloride salt rather than the phosphate ester as in vivo, clindamycin is 
rapidly hydrolysed to the free base by the phosphatase enzyme [11]. Upon dissolving clindamycin phosphate in 
water, the clindamycin free base is not liberated  unlike when clindamycin hydrochloride is dissolved. To observe 
this, in a separate chromatographic run, solutions of both clindamycin phosphate and clindamycin hydrochloride 
(100µg/ml each) were prepared in water and analysed using different chromatographic conditions. Chromatographic 
conditions consisted of a mobile phase made up of phosphate buffer (pH 3) and acetonitrile (70:30 v/v) at a flow rate 
of 1ml/min. The wavelength was set at 205nm and the temperature was set at 25°C. Analysis was conducted using 
an Agilent® 1200 Infinity series unit and separation took place on an ACE® 5 C18 HPLC column (250x 4.6mm; 
5µm particle size).  
 
Preparation of Stock Solutions 
The stock solution was prepared by accurately weighing 100mg of the standard clindamycin hydrochloride powder 
and dissolving it in 100ml HPLC grade water (1mg/ml). A stock solution of Phenobarbital (known chemically as 5-
ethyl-5-phenyl-1,3-diazinane-2,4,6-trione) was prepared by dissolving 100mg of Phenobarbital powder in 100ml of 
methanol.  
 
Sample Preparation 
Protein precipitation was chosen for the deproteinization of clindamycin in plasma. Drug- free plasma was spiked 
with clindamycin and the internal standard phenobarbital (50µl of 20µl/ml). Phenobarbital was chosen as the internal 
standard as it exhibits similar chromatographic behaviour to clindamycin under the conditions used. Three drops of 
10M phosphate buffer at a pH of 4.00 were added to the spiked plasma followed by 1ml of ice cold acetonitrile. This 
was vortex- mixed for two minutes. The samples were centrifuged at 1300g for a total of 5 minutes. The clear 
supernatant was decanted into a clean glass container and placed in a Turbovap®LV water bath set at 50°C for 
evaporation of the organic layer. The dried residue was reconstituted with 100µl mobile phase, transfered to smaller 
test tubes and centrifuged again at 1300g for 2 minutes. The additional centrifugation step avoided premature 
contamination of the guard column and column. The clear supernatant (50µl) was injected into the HPLC unit and 
analysed.  
 
Validation Parameters 
The developed method was validated as per ICH guidelines [27] with respect to linearity, precision, selectivity, limit 
of detection (LOD) and limit of quantification (LOQ), recovery, accuracy and stability.  
 
Linearity 
Seven calibration standards were prepared within the range of 0.5 to 20µg/ml (0.5, 1, 2, 5, 10, 15, 20 µg/ml) thus 
meeting the needs of the purpose of this study where the average minimum and maximum concentrations of 
clindamycin in human plasma range between 1.1 and 14.1 µg/ml respectively [28]. The standard curve was obtained 
by plotting the average ratio of the area under the peak (AUP) for clindamycin to that for phenobarbitone against 
concentration (µg/ml).  
 
Precision 
The degree of agreement amongst individual replicate analysis was determined by the evaluation of interday 
(intermediate) and intraday (repeatability) precision. For interday precision each of the the seven different 
concentrations were analysed once every day for five consequtive days. The degree of agreement was determined 
through the relative standard deviation (RSD) by dividing the standard deviation by the mean value obtained for 
each set of concentrations and multiplying by 100. Intraday precision was determined by analysing all the seven 
concentrations five times each within the same day and assessing the degree of agreement by comparing the 
calculated RSD values.  
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Accuracy and Recovery 
Accuracy of the developed method was assessed in triplicate at three concentrations (15,10 and 1µg/ml). The 
percentage recovery was calculated by establishing the ratio of clindamycin detected (µg/ml) and the standard 
clindamycin concentration injected (µg/ml). 
 
Selectivity  
When testing for  selectivity one is confirming that the method is measuring only what it is intended to measure and 
that the method is free from interferences which may lead to incorrect results [29]. This was done by running a blank 
run on drug free plasma and confirming the absence of a peak where clindamycin  usually elutes.  
 
Limit of Detection and Limit of Quantification  
The limit of detection (LOD) and limit of quantification (LOQ) were determined by injecting decreasing 
concentrations of clindamycin  and establishing the minimum level at which the analyte of interest can be easily 
detected and quantified respectively. This was done in triplicate every time.  
 
Stability of spiked plasma samples 
Three chosen concentrations (15, 5, 1 µg/ml) were analysed after 1 week and 4 weeks following storage at -20°C.   
 
RESULTS AND DISCUSSION 
 
Clindamycin Hydrochloride vs Clindamycin Phosphate 
When observing chromatographic results it could be noted that the peak given when the solution of clindamycin 
hydrochloride was injected eluted with a  retention time which was longer (Fig. 2) than that of the peak given when 
clindamycin phosphate (Fig. 3) was injected. This means that upon dissolving in water, clindamycin hydrochloride 
liberates the more hydrophobic clindamycin free base whilst clindamycin phosphate does not. Method development 
for the quantification of active clindamycin in plasma to be then used for patient plasma samples would therefore be 
more appropriately done using the hydrochloride salt rather than the phosphate ester.  
 
 
Fig. 2: Clindamycin Hydrochloride (100µg/ml) analyzed in water 
Martina Mifsud et al                 J. Chem. Pharm. Res., 2014, 6(1):696-704       
______________________________________________________________________________ 
700 
 
Fig. 3: Clindamycin Phosphate (100µg/ml) analyzed in Water 
 
Optimization of chromatographic conditions 
During method development clindamycin was eluting at 4.60 minutes whilst phenobarbitone was eluting after 14 
minutes when passing through the column at a flow rate of 1ml/min. To make the method more time efficient the 
flow rate was increased to 1.5ml/min. This reduced the retention time of phenobarbitone to 7 minutes whilst still 
maintaining appropriate peak shape and resolution (Fig. 4). 
 
 
 
Fig. 4: Chromatogram of Clindamycin (20 µg/ml) in plasma with Phenobarbitone as internal standard 
 
Linearity 
The calibration curve is given in Fig. 5 with the coefficient of determination r2 being 0.990 Table 1.  
 
Table 1: Statistical (SPSS) results for Calibration Curve 
 
R R Square Adjusted R Square Std. Error 
0.995 0.990 0.987 0.028 
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Fig. 5: Linearity Graph of Clindamycin in plasma (20, 15, 10, 5, 2, 1 and 0.5µg/ml) 
 
Stability of Sample Solution 
The clindamycin-spiked plasma was found to be stable after being stored at -20°C for 1 and 4 weeks respectively. 
Results showed that there was no significant change in the quantity of clindamycin detected in the three 
concentrations analysed (% RSD all under 5.4) Table 2.  
 
Table 2: Stability of Plasma Sample 
 
Concentration of Standard 
(µg/ml) 
Post-preparation time 
(weeks) 
Calculated Quantity of Clindamycin  
(µg/ml) %RSD 
15 1 14.89  
15 
15 
5 
5 
5 
1 
1 
1 
1 
1 
1 
1 
1 
1 
14.76 
14.63 
4.84 
4.90 
4.90 
0.92 
0.95 
0.50 
 
 
0.40 
 
 
1.27 
1 1 0.96  
15 
15 
15 
5 
5 
4 
4 
4 
4 
4 
14.86 
14.80 
14.86 
4.90 
4.88 
 
0.23 
 
 
0.40 
5 
1 
1 
4 
4 
4 
4.92 
0.90 
0.89 
 
 
5.40 
1 4 0.99  
 
Precision  
The percentage relative standard deviation (% RSD) of the quantities of clindamycin detected during the intraday 
study was found to range between 1.29 and 13.80 for the seven concentrations analyzed Table 3. Interday precision 
% RSD values were all below 11.92% Table 4. 
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Table 3: Intraday Validation (n=5) 
 
Conc (µg ml-1) Mean Conc. SD %RSD 
20 20.07 0.26 1.29 
15 15.19 0.50 3.32 
10 10.40 0.65 6.22 
5 4.63 0.29 6.28 
2 1.81 0.08 4.22 
1 1.04 0.08 8.04 
0.5 0.53 0.07 13.80 
 
Table 4: Interday Validation Results Run Over 5 days 
 
Conc (µg ml-1) Mean Conc. SD %RSD 
20 19.24 0.45 2.30 
15 14.85 0.07 0.49 
10 10.03 0.52 5.20 
5 4.72 0.07 1.59 
2 1.89 0.14 7.36 
1 0.95 0.06 6.10 
0.5 0.52 0.06 11.92 
 
Limit of Quantification (LOQ) and Limit of Detection (LOD) 
Concentrations of LOQ and LOD were found to be 0.2µg/ml and 0.1µg/ml respectively.  
 
Accuracy and Recovery 
The quantitative recoveries of clindamycin in plasma achieved ranged from 82 to 107%. The mean recoveries for all 
three concentrations analyzed are given in Table 5.  
 
Table 5: Recovery Studies 
 
 
 
 
 
 
 
aMean concentration of three trials. 
 
Selectivity 
The selectivity of the method was confirmed by analysing blank plasma and noting the absence of any peak at the 
retention time where clindamycin usually elutes (Fig. 6).  
 
 
 
Fig. 6: Chromatogram of Blank Plasma 
 
CONCLUSION 
 
The proposed method is one which is reproducible and simple to use. It does not involve multiple sample 
preparation steps and utilises minimal amounts of organic solvents. When compared to other published methods, the 
newly developed method in this study had a relatively short retention time for clindamycin. The only two studies 
which had a shorter retention time for clindamycin were those by Martens- Lodenhoffer and Banditt and by Catena 
et al [12,17]. The former study, apart from making use of a higher temperature of the stationary phase, also made 
use of a shorter column. This was probably the reason why clindamycin had a shorter retention time. Since this 
Drug Content in µg ml-1 Mean Recovery (%) 
Theoretical Practicala 
15 14.90 97.67 
10 9.93 99.07 
1 0.93 92.67 
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method is later to be used to quantify clindamycin in the plasma of PAD patients who will probably be on 
poylpharmacy to treat co- morbidities, the use of a shorter column than the one used in this study could compromise 
resolution between different medications which elute. The results given by Catena et al for the retention time of 
clindamycin were difficult to correlate with the rest of the other parameters since in the article, the aqueous phase 
used in combination with methanol is not specified making interpretation of values dubious [17]. Using the 
developed method relatively low limits of detection and quantification were achieved. Although previously 
published methods for the analysis of clindamycin reported to achieve lower limits of detection and quantification 
[10,11] the ones attained in this one were adequate for the purpose of the study. The concentration of clindamycin in 
plasma over an 8 hour period ranges from 16µg/ml to 2µg/ml [26]. The limit of quantification lies well below the 
lowest reported concentration for clindamycin in plasma and therefore this developed method serves well the 
intended purpose.   
 
The use of such a proposed HPLC method may help in the tailoring of more individualised dosing of antibiotics in 
patients with peripheral artery disease where antibacterial dose reaching the site of infection may be compromised.  
In patients with peripheral artery disease, foot infections are common and effective use of antibacterial agents may 
reduce amputations [30].  However the distribution of the antibacterials in the peripheries changes in peripheral 
arterial disease from that in healthy individuals [31].  Development of methods such as the one proposed in this 
study which can be easily carried out to support clinical decisions in antibacterial dosing are useful.  Future work 
aims to apply this simple and efficient method to quantify clindamycin in the plasma of PAD patients.  
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